← ACW

ACWACTINOGEN MEDICAL LIMITED

Announcement history available from 1 August 2025

Fromto
Date / TimeTitleTypeMSReport Codes
21 Aug 2026, 00:46Appendix 3Y - Dr George MorstynDirector Interests—02009
21 Aug 2026, 00:40Application for quotation of securities - ACWOther—06020
18 Aug 2026, 00:26Appendix 3Y-Malcolm McComasDirector Interests—02009
18 Aug 2026, 00:14Application for quotation of securities - ACWOther—06020
12 Aug 2026, 19:14ACW webinar today, The future of Alzheimers treatmentPresentations—03026, 14014
11 Aug 2026, 02:38Updated Securities Trading PolicyCompany Administration—14013
10 Aug 2026, 21:33Application for quotation of securities - ACWOther—06020
10 Aug 2026, 19:12Notification of cessation of securities - ACWOther—06027
6 Aug 2026, 18:27ACW Bioshares presentation, strong cortisol rationalePresentations—03026
5 Aug 2026, 22:43Application for quotation of securities - ACWOther—06020
5 Aug 2026, 22:08ACW webinar on the future of Alzheimers treatmentPresentations—14014
30 July 2026, 20:03June 2026 Quarterly activity report & Appendix 4CQuarterly ReportsMS19004, 19009
29 July 2026, 01:19Application for quotation of securities - ACWOther—06020
21 July 2026, 23:41Application for quotation of securities - ACWOther—06020
20 July 2026, 19:33Xanamem depression trial published in British J PsychiatryCompany UpdateMS11001, 12008
14 July 2026, 03:24Notification of buy-back - ACWOther—06023
13 July 2026, 18:32ACW AAIC poster presentation of XanaMIA trial baseline dataCompany Update—11001
8 July 2026, 18:40ACW senior management presentation at AAIC & internationallyPresentations—03026
26 June 2026, 00:11Becoming a substantial holderSubstantial Holders—02001
24 June 2026, 23:48Appendix 3Y x 5Director Interests—02009
24 June 2026, 23:45Application for quotation of securities - ACWOther—06020
23 June 2026, 20:39Results of MeetingMeetings & Governance—08003
19 June 2026, 01:02Application for quotation of securities - ACWOther—06020
18 June 2026, 18:57ACW third positive XanaMIA trial data committee reviewCompany UpdateMS11001
1 June 2026, 18:52ACW presents XanaMIA population and screening data at ADRFCompany Update—11001
28 May 2026, 19:51Actinogen receives positive scientific advice from EMACompany UpdateMS11001
22 May 2026, 00:54Application for quotation of securities - ACWOther—06020
22 May 2026, 00:44Letter to Shareholders, Notice of GM & Proxy FormMeetings & Governance—08004, 08007, 16002
19 May 2026, 00:29Application for quotation of securities - ACWOther—06020
13 May 2026, 20:16ACW CEO options exercise and expiry reminderSecurities Administration—06009
13 May 2026, 20:12Appendix 3Y - Dr Steven GourlayDirector Interests—02009
13 May 2026, 20:08Application for quotation of securities - ACWOther—06020
11 May 2026, 21:44Application for quotation of securities - ACWOther—06020
4 May 2026, 18:17Notification of cessation of securities - ACWOther—06027
29 Apr 2026, 19:17Correction-March2026 quarterly activity report & Appendix 4CQuarterly ReportsMS19003, 19008
29 Apr 2026, 19:05ACW December 2025 quarterly activity report & Appendix 4CQuarterly ReportsMS19003, 19008
2 Apr 2026, 21:53Notification of buy-back - ACWOther—06023
1 Apr 2026, 19:59ACW XanaMIA Alzheimers open label trial commencesCompany UpdateMS11001
27 Mar 2026, 01:06Appendix 3Y x 5Director Interests—02009
27 Mar 2026, 00:55Cleansing NoticeSecurities Administration—06018
27 Mar 2026, 00:50Application for quotation of securities - ACWOther—06020
18 Mar 2026, 21:50Results of General MeetingMeetings & Governance—08003
16 Mar 2026, 20:04CEO loan-funded long-term incentive shares amendmentCompany Administration—12008
6 Mar 2026, 01:42Application for quotation of securities - ACWOther—06020
2 Mar 2026, 20:10Application for quotation of securities - ACWOther—06020
27 Feb 2026, 20:33ACW successfully completes $16.8m Placement and SPPCapital RaisingMS06017
27 Feb 2026, 00:47Application for quotation of securities - ACWOther—06020
26 Feb 2026, 21:27ACW HY26 results - XanaMIA pivotal Alzheimers trial progressFinancial ResultsMS03004
26 Feb 2026, 21:26Actinogen HY2025 financial report and Appendix 4DFinancial ResultsMS03004, 03009, 03010, 03015, 03019
14 Feb 2026, 01:02Letter to Shareholders, Notice of Meeting & Proxy FormMeetings & Governance—08004, 08007, 16002
1–50 of 105
1 / 3